Understanding the Risks Associated with AAV Vector Genome Integration

Time: 3:30 pm
day: Day Two


• Assessing how real the risk of AAV vector genome integration is in humans

• Exploring the current protocols to identify oncogenic risk and identifying elements to improve as the severity of risk is more understood

• Highlighting the best methods to monitor genome integration before, during and after trials